Liraglutide (Victoza) vs Semaglutide (Rybelsus)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT00318461 · Phase 3 · completed

This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.

Next expected readout: June 2027 · NCT03883412 (registry estimate)

Reported efficacy

Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00318461

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT06050577 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Victoza)Semaglutide (Rybelsus)
HbA1c, change-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082
Body weight, change (kg)-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082
HbA1c below 7%63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
—Not posted · NCT07271251
Fasting plasma glucose, change-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
3-point MACE (% with event)13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT0117904812% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result

HbA1c, change

Liraglutide (Victoza)
-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422
Semaglutide (Rybelsus)
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082

Body weight, change (kg)

Liraglutide (Victoza)
-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
Semaglutide (Rybelsus)
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082

HbA1c below 7%

Liraglutide (Victoza)
63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
Semaglutide (Rybelsus)
—Not posted · NCT07271251

Fasting plasma glucose, change

Liraglutide (Victoza)
-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
Semaglutide (Rybelsus)
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080

3-point MACE (% with event)

Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
Semaglutide (Rybelsus)
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
18 other shared endpoints and safety

Coverage. Liraglutide (Victoza): 22 of 22 rows · Semaglutide (Rybelsus): 21 of 22 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Victoza)
Rows use multiple source trials
Semaglutide (Rybelsus)
Rows use multiple source trials
BMI
absolute change · kg
-1.3 vs -1.2 Oral Antidiabetic Drug kg @ 104wk1.8 mga,b,c
NCT02730377 · Phase 4 · registry result, not featured evidence
-0.9 vs -0.3 Sitagliptin kg @ 104wka,b,c
NCT02849080 · Phase 3 · registry result, not featured evidence
DBP
absolute change · mmHg
-0.72 vs -1.12 placebo mmHg @ 26wkb,c
NCT02964247 · Phase 3 · registry result, not featured evidence
-2 vs -2 placebo mmHg @ 26wk14 mgd,b,c
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1 vs -2 placebo mmHg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0 vs -2 placebo mmHg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-27 vs -11.97 placebo mg @ 26wkb,c
NCT02964247 · Phase 3 · registry result, not featured evidence
-32.5 vs 0 placebo mg @ 26wk14 mgd,b,c
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-32.28 vs 0 placebo mg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-19.07 vs 0 placebo mg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=200) @ 32wkd,b,c,e
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
-1.3% (n=180) @ 104wkb,c,e
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain
event count · % of participants
13.7% (n=270) vs 8.3% (n=265) Insulin Degludec @ 52wk*d,b,c
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 37 Participants as posted
show 1 more dose
52% (n=271) vs 8.3% (n=265) Insulin Degludec @ 52wk*
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 141 Participants as posted
45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*b,c
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted
HbA1c Less Than 7%
event count · % of participants
48.2% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mgf,b,c
Yes
NCT01541215 · Phase 3 · converted to % from 27 Participants as posted
2 other source trials
89.1% (n=275) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted
76.2% (n=273) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 208 Participants as posted
58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*f,b,c
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted
HbA1c Less Than 7%
event count · % of participants
No placebo or comparator arm
89.5% (n=200) @ 32wk*d,b,c,e
NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 179 participants as posted
show 1 more dose
89.9% (n=189) @ 32wk*
NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 170 participants as posted
56.1% (n=180) @ 104wk*b,c,e
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 101 Participants as posted
HbA1c Less Than or Equal to 6.5
event count · % of participants
44.6% (n=56) vs 25% (n=52) placebo @ 52wk*1.8 mgf,b,c
Yes
NCT01541215 · Phase 3 · converted to % from 25 Participants as posted
39% (n=326) vs 23.2% (n=293) Other Oral Glucose-lowering Medication @ 52wk*f,b,c
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 127 Participants as posted
1 other source trial
33% (n=230) vs 12.2% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 76 Participants as posted
HDL Cholesterol
ratio to baseline · ratio
1.01 vs 1.02 Insulin Degludec ratio @ 26wkd,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
1.03 vs 1.02 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
1.01 vs 1.07 Empagliflozin 25 mg ratio @ 26wk14 mgb,c
NCT02863328 · Phase 3
21 other source trials
0.98 vs 0.99 Sitagliptin ratio @ 26wk14 mg
NCT02607865 · Phase 3
0.97 vs 0.99 Sitagliptin ratio @ 26wk3 mg
NCT02607865 · Phase 3
0.99 vs 0.99 Sitagliptin ratio @ 26wk7 mg
NCT02607865 · Phase 3
1.02 vs 1.02 placebo ratio @ 26wk14 mg
NCT02863419 · Phase 3
1.02 vs 1.02 placebo ratio @ 26wk14 mg
NCT02827708 · Phase 3
0.98 vs 1.01 placebo ratio @ 26wk14 mg
NCT03021187 · Phase 3
1 vs 1.01 placebo ratio @ 26wk3 mg
NCT03021187 · Phase 3
0.98 vs 1.01 placebo ratio @ 26wk7 mg
NCT03021187 · Phase 3
1.05 vs 1.02 placebo ratio
NCT02692716 · Phase 3
1 vs 1 Sitagliptin ratio @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1.02 vs 1 Sitagliptin ratio @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1.01 vs 1 Sitagliptin ratio @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1.02 vs 1.04 placebo ratio @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1.03 vs 1.04 placebo ratio @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1.02 vs 1.04 placebo ratio @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.96 vs 1.03 placebo ratio @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.97 vs 1.03 placebo ratio @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.98 vs 1.03 placebo ratio @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
1 vs 0.99 Dulaglutide ratio @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.02 vs 0.99 Dulaglutide ratio @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.99 vs 0.99 Dulaglutide ratio @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
LDL Cholesterol
ratio to baseline · ratio
0.92 vs 1.01 Insulin Degludec ratio @ 26wkd,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.96 vs 1.01 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.96 vs 1.03 Empagliflozin 25 mg ratio @ 26wk14 mgb,c
NCT02863328 · Phase 3
21 other source trials
0.98 vs 1.02 Sitagliptin ratio @ 26wk14 mg
NCT02607865 · Phase 3
1.02 vs 1.02 Sitagliptin ratio @ 26wk3 mg
NCT02607865 · Phase 3
0.98 vs 1.02 Sitagliptin ratio @ 26wk7 mg
NCT02607865 · Phase 3
0.95 vs 0.99 placebo ratio @ 26wk14 mg
NCT02863419 · Phase 3
0.97 vs 1 placebo ratio @ 26wk14 mg
NCT02827708 · Phase 3
0.93 vs 1.03 placebo ratio @ 26wk14 mg
NCT03021187 · Phase 3
0.98 vs 1.03 placebo ratio @ 26wk3 mg
NCT03021187 · Phase 3
0.93 vs 1.03 placebo ratio @ 26wk7 mg
NCT03021187 · Phase 3
0.96 vs 0.97 placebo ratio
NCT02692716 · Phase 3
0.98 vs 1.01 Sitagliptin ratio @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1.02 vs 1.01 Sitagliptin ratio @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.98 vs 1.01 Sitagliptin ratio @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.94 vs 1 placebo ratio @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1 vs 1 placebo ratio @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1 vs 1 placebo ratio @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.85 vs 1.03 placebo ratio @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.87 vs 1.03 placebo ratio @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.89 vs 1.03 placebo ratio @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.87 vs 0.88 Dulaglutide ratio @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.92 vs 0.88 Dulaglutide ratio @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.88 vs 0.88 Dulaglutide ratio @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
PPG Excursion
absolute change · mmol/L
-0.747 vs -0.397 placebo mmol/L @ 52wk1.8 mgg,c
NCT01541215 · Phase 3
2 other source trials
-0.74 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.01 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.4 Empagliflozin 25 mg mmol/L @ 52wk14 mgg,c
NCT02863328 · Phase 3
13 other source trials
-0.7 vs -0.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-0.5 vs -0.4 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-0.3 vs -0.3 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-2 vs -0.1 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.1 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.1 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.7 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.7 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.7 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-1.95 vs -3.35 placebo mmHg @ 26wkb,c
NCT02964247 · Phase 3 · registry result, not featured evidence
-4 vs -2 placebo mmHg @ 26wk14 mgd,b,c
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2 vs -2 placebo mmHg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1 vs -2 placebo mmHg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
SMBG 7-point
absolute change · mmol/L
-2.309 vs -0.748 placebo mmol/L @ 52wk1.8 mgg,c
NCT01541215 · Phase 3
-2.3 vs -2.1 Empagliflozin 25 mg mmol/L @ 52wk14 mgg,c
NCT02863328 · Phase 3
13 other source trials
-1.8 vs -1.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-1.3 vs -1.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-1.5 vs -1.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-2.2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-1.6 vs -0.9 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-1.7 vs -0.9 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-3.1 vs 0 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.7 vs 0 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.2 vs 0 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.7 vs -2.6 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.6 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Total Cholesterol
ratio to baseline · ratio
0.94 vs 0.99 Insulin Degludec ratio @ 26wkd,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.97 vs 0.99 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.96 vs 1.02 Empagliflozin 25 mg ratio @ 26wk14 mgb,c
NCT02863328 · Phase 3
21 other source trials
0.97 vs 1 Sitagliptin ratio @ 26wk14 mg
NCT02607865 · Phase 3
1 vs 1 Sitagliptin ratio @ 26wk3 mg
NCT02607865 · Phase 3
0.98 vs 1 Sitagliptin ratio @ 26wk7 mg
NCT02607865 · Phase 3
0.96 vs 0.99 placebo ratio @ 26wk14 mg
NCT02863419 · Phase 3
0.97 vs 1 placebo ratio @ 26wk14 mg
NCT02827708 · Phase 3
0.95 vs 1.03 placebo ratio @ 26wk14 mg
NCT03021187 · Phase 3
0.99 vs 1.03 placebo ratio @ 26wk3 mg
NCT03021187 · Phase 3
0.95 vs 1.03 placebo ratio @ 26wk7 mg
NCT03021187 · Phase 3
0.97 vs 0.98 placebo ratio
NCT02692716 · Phase 3
0.96 vs 0.99 Sitagliptin ratio @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1 vs 0.99 Sitagliptin ratio @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.96 vs 0.99 Sitagliptin ratio @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.94 vs 1 placebo ratio @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.99 vs 1 placebo ratio @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.98 vs 1 placebo ratio @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.89 vs 1 placebo ratio @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.92 vs 1 placebo ratio @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.93 vs 1 placebo ratio @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.91 vs 0.92 Dulaglutide ratio @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.96 vs 0.92 Dulaglutide ratio @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.91 vs 0.92 Dulaglutide ratio @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Triglyceride
ratio to baseline · ratio
0.88 vs 0.82 Insulin Degludec ratio @ 26wkd,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.9 vs 0.82 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.88 vs 0.9 Empagliflozin 25 mg ratio @ 26wk14 mgb,c
NCT02863328 · Phase 3
21 other source trials
0.92 vs 0.97 Sitagliptin ratio @ 26wk14 mg
NCT02607865 · Phase 3
0.99 vs 0.97 Sitagliptin ratio @ 26wk3 mg
NCT02607865 · Phase 3
0.96 vs 0.97 Sitagliptin ratio @ 26wk7 mg
NCT02607865 · Phase 3
0.89 vs 1.01 placebo ratio @ 26wk14 mg
NCT02863419 · Phase 3
0.87 vs 0.95 placebo ratio @ 26wk14 mg
NCT02827708 · Phase 3
0.91 vs 0.99 placebo ratio @ 26wk14 mg
NCT03021187 · Phase 3
0.97 vs 0.99 placebo ratio @ 26wk3 mg
NCT03021187 · Phase 3
0.92 vs 0.99 placebo ratio @ 26wk7 mg
NCT03021187 · Phase 3
0.92 vs 0.97 placebo ratio
NCT02692716 · Phase 3
0.86 vs 0.91 Sitagliptin ratio @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.96 vs 0.91 Sitagliptin ratio @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.86 vs 0.91 Sitagliptin ratio @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.87 vs 0.93 placebo ratio @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.96 vs 0.93 placebo ratio @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.9 vs 0.93 placebo ratio @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.93 vs 0.87 placebo ratio @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
1.03 vs 0.87 placebo ratio @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.94 vs 0.87 placebo ratio @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.96 vs 0.93 Dulaglutide ratio @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.03 vs 0.93 Dulaglutide ratio @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.91 vs 0.93 Dulaglutide ratio @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
VLDL Cholesterol
ratio to baseline · ratio
0.9 vs 0.84 Insulin Degludec ratio @ 26wkd,b,c
NCT03172494 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.92 vs 0.84 Insulin Degludec ratio @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
0.89 vs 0.91 Empagliflozin 25 mg ratio @ 26wk14 mgb,c
NCT02863328 · Phase 3
13 other source trials
0.91 vs 0.97 Sitagliptin ratio @ 26wk14 mg
NCT02607865 · Phase 3
0.99 vs 0.97 Sitagliptin ratio @ 26wk3 mg
NCT02607865 · Phase 3
0.96 vs 0.97 Sitagliptin ratio @ 26wk7 mg
NCT02607865 · Phase 3
0.9 vs 1.02 placebo ratio @ 26wk14 mg
NCT02863419 · Phase 3
0.94 vs 0.98 Sitagliptin ratio @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1.05 vs 0.98 Sitagliptin ratio @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.94 vs 0.98 Sitagliptin ratio @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
0.93 vs 0.87 placebo ratio @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
1.02 vs 0.87 placebo ratio @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.94 vs 0.87 placebo ratio @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.96 vs 0.93 Dulaglutide ratio @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.03 vs 0.93 Dulaglutide ratio @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0.92 vs 0.93 Dulaglutide ratio @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Waist Circumference Change
absolute change · cm
2.5 vs 3.4 Insulin Degludec cm @ 52wkd,b,c
NCT02607306 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.1 vs 3.4 Insulin Degludec cm @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-3.7 vs -2.9 Empagliflozin 25 mg cm @ 52wk14 mgb,c
NCT02863328 · Phase 3
14 other source trials
-2.6 vs -0.5 Sitagliptin cm @ 52wk14 mg
NCT02607865 · Phase 3
-1.3 vs -0.5 Sitagliptin cm @ 52wk3 mg
NCT02607865 · Phase 3
-2.3 vs -0.5 Sitagliptin cm @ 52wk7 mg
NCT02607865 · Phase 3
-4.4 vs -1.7 placebo cm @ 52wk14 mg
NCT02863419 · Phase 3
-4 vs 0.3 placebo cm @ 52wk14 mg
NCT03021187 · Phase 3
-0.8 vs 0.3 placebo cm @ 52wk3 mg
NCT03021187 · Phase 3
-2.3 vs 0.3 placebo cm @ 52wk7 mg
NCT03021187 · Phase 3
-2.6 vs -0.7 Sitagliptin cm @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-2.7 vs -0.9 placebo cm @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.2 vs -0.9 placebo cm @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1 vs -0.9 placebo cm @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.7 vs 0.7 Dulaglutide cm @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.1 vs 0.7 Dulaglutide cm @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs 0.7 Dulaglutide cm @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
Weight
percent change · % of baseline
-7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkb,c,h
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
-3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wkb,c,h
NCT02849080 · Phase 3 · registry result, not featured evidence
Dropout rate
21.1%1.8 mg dailyi
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
18.3%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
3%
NCT01179048 · Phase 3
15.2%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
41.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
55.2%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
6.3%
NCT02765399 · Phase 4 · registry result, not featured evidence
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
8.6%
NCT01505673 · Phase 4 · registry result, not featured evidence
7.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
14.7%
NCT02008682 · Phase 4 · registry result, not featured evidence
15.1%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
16.1%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
55.1%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
1.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
3.7%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
6.9%14 mgj
NCT02906930 · Phase 3
show 39 more results
8%7 mg
NCT02906930 · Phase 3
3.4%3 mg
NCT02906930 · Phase 3
2.7%14 mg
NCT02863328 · Phase 3
5.8%14 mg
NCT02607865 · Phase 3
6.4%7 mg
NCT02607865 · Phase 3
7.1%3 mg
NCT02607865 · Phase 3
2.8%14 mg
NCT02863419 · Phase 3
3.1%14 mg
NCT02827708 · Phase 3
3.3%14 mg
NCT03021187 · Phase 3
4.9%7 mg
NCT03021187 · Phase 3
5.4%3 mg
NCT03021187 · Phase 3
1.5%
NCT03914326 · Phase 3
0.3%
NCT02692716 · Phase 3
11.8%
NCT05035082 · Phase 4 · registry result, not featured evidence
5.4%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
5.6%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.4%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
7.2%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
5%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.6%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
2.1%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
2.3%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.5%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
2.3%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
11.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
11.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
5.7%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
8.6%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
12%1.8 mg dailyi
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.5%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT01179048 · Phase 3
0%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—
NCT03260881 · Phase 4 · registry result, not featured evidence
7.4%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
7.9%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
—
NCT02765399 · Phase 4 · registry result, not featured evidence
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
—
NCT02014740 · Phase 4 · registry result, not featured evidence
—
NCT02299388 · Phase 4 · registry result, not featured evidence
—
NCT01505673 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01973231 · Phase 4 · registry result, not featured evidence
—
NCT02008682 · Phase 4 · registry result, not featured evidence
6.4%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
8.3%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
—
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
—
NCT02964247 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.2%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
—14 mgj
NCT02906930 · Phase 3
show 39 more results
—7 mg
NCT02906930 · Phase 3
—3 mg
NCT02906930 · Phase 3
—14 mg
NCT02863328 · Phase 3
—14 mg
NCT02607865 · Phase 3
—7 mg
NCT02607865 · Phase 3
—3 mg
NCT02607865 · Phase 3
—14 mg
NCT02863419 · Phase 3
—14 mg
NCT02827708 · Phase 3
—14 mg
NCT03021187 · Phase 3
—7 mg
NCT03021187 · Phase 3
—3 mg
NCT03021187 · Phase 3
—
NCT03914326 · Phase 3
—
NCT02692716 · Phase 3
—
NCT05035082 · Phase 4 · registry result, not featured evidence
—14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Serious AEs
6.6%1.8 mg dailyi
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
10.4%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
49.7%
NCT01179048 · Phase 3
13.6%1.8 mg
NCT01541215 · Phase 3
13.5%1.8 mg
NCT01541215 · Phase 3
4.2%1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
38.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
9.4%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
0%
NCT02765399 · Phase 4 · registry result, not featured evidence
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
2.9%
NCT01505673 · Phase 4 · registry result, not featured evidence
3%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.9%
NCT01973231 · Phase 4 · registry result, not featured evidence
1.6%
NCT02008682 · Phase 4 · registry result, not featured evidence
1.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02889510 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
7.8%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
5.1%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
0%
NCT01937598 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
1.1%14 mgj
NCT02906930 · Phase 3
show 39 more results
1.7%7 mg
NCT02906930 · Phase 3
2.9%3 mg
NCT02906930 · Phase 3
6.6%14 mg
NCT02863328 · Phase 3
9.5%14 mg
NCT02607865 · Phase 3
10.1%7 mg
NCT02607865 · Phase 3
13.7%3 mg
NCT02607865 · Phase 3
10.9%14 mg
NCT02863419 · Phase 3
10.4%14 mg
NCT02827708 · Phase 3
6.6%14 mg
NCT03021187 · Phase 3
10.5%7 mg
NCT03021187 · Phase 3
13.6%3 mg
NCT03021187 · Phase 3
47.9%
NCT03914326 · Phase 3
18.9%
NCT02692716 · Phase 3
10.2%
NCT05035082 · Phase 4 · registry result, not featured evidence
9.9%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.2%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
10.7%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
3%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.9%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
7.7%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
4.6%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
9.5%Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
14.2%Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
9%Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
0%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
4.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
5.4%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
3%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
6.9%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
1.4%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1.8 mg dailyi
nausea 21.5%
diarrhoea 16.5%
nasopharyngitis 14.9%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 32 more results
1.2 mg daily
nausea 17.5%
nasopharyngitis 15%
headache 14.2%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6 mg daily
nasopharyngitis 17.8%
diarrhoea 12.8%
nausea 12.4%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
1.8 mg
nausea 28.8% (placebo 13.2%)
vomiting 25.8% (placebo 8.8%)
diarrhoea 22.7% (placebo 16.2%)
NCT01541215 · Phase 3
1.8 mg
nasopharyngitis 3.8% (placebo 27.9%)
vomiting 3.8% (placebo 8.8%)
abdominal pain 1.9% (placebo 7.4%)
NCT01541215 · Phase 3
1.8 mg
hyperglycaemia 2.1% (placebo 5.9%)
pharyngitis 2.1% (placebo 5.9%)
abdominal pain 0% (placebo 7.4%)
NCT01541215 · Phase 3
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence
1.8 mg
nausea 6.6%
NCT02730377 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 14.3%)
NCT02765399 · Phase 4 · registry result, not featured evidence
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nausea 29.1%
NCT02014740 · Phase 4 · registry result, not featured evidence
nausea 31.4% (placebo 19.4%)
decreased in apetite 17.1% (placebo 11.1%)
diarrhea 11.4% (placebo 8.3%)
NCT01505673 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 16.3%
decreased appetite 8.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 12.4%
lipase increased 8.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
nausea 14.8%
decreased appetite 10.9%
diarrhoea 8.2%
NCT02008682 · Phase 4 · registry result, not featured evidence
vomiting 5.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal disorders 27.1% (placebo 5.7%)
general disorders and administration site conditions 2.9% (placebo 0%)
nervous system disorders 2.9% (placebo 2.9%)
NCT02889510 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
decreased appetite 14.4%
diarrhoea 14.4%
lipase increased 12.2%
NCT03172494 · Phase 3 · registry result, not featured evidence
nausea 37.2% (placebo 2.7%)
diarrhea 17.9% (placebo 17.3%)
allergic reaction to liraglutide 1.3% (placebo 0%)
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nausea 26.2% (placebo 6%)
decreased appetite 9.4% (placebo 0%)
diarrhoea 9.4% (placebo 3%)
NCT02964247 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 34.4%
constipation 13.9%
diarrhoea 8.8%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
headache 12.5% (placebo 12.5%)
asympomatic hyppglycaemia 6.3% (placebo 0%)
nausea 6.3% (placebo 0%)
NCT01937598 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
14 mgj
nausea 16% (placebo 5.6%)
vomiting 6.9% (placebo 2.2%)
decreased appetite 5.1% (placebo 0.6%)
NCT02906930 · Phase 3
show 38 more results
7 mg
nasopharyngitis 6.3% (placebo 3.4%)
headache 5.7% (placebo 5.1%)
diarrhoea 5.1% (placebo 2.2%)
NCT02906930 · Phase 3
3 mg
diarrhoea 8.6% (placebo 2.2%)
nausea 8% (placebo 5.6%)
nasopharyngitis 5.7% (placebo 3.4%)
NCT02906930 · Phase 3
14 mg
nausea 19.8%
diarrhoea 9.3%
vomiting 7.3%
NCT02863328 · Phase 3
14 mg
nausea 15.1%
diarrhoea 12%
nasopharyngitis 10.1%
NCT02607865 · Phase 3
7 mg
nausea 13.4%
diarrhoea 11.4%
nasopharyngitis 10.6%
NCT02607865 · Phase 3
3 mg
nasopharyngitis 11.4%
diarrhoea 9.4%
upper respiratory tract infection 7.7%
NCT02607865 · Phase 3
14 mg
nausea 19.3% (placebo 3.5%)
diarrhoea 15.1% (placebo 7.7%)
nasopharyngitis 14.4% (placebo 10.6%)
NCT02863419 · Phase 3
14 mg
nausea 19% (placebo 7.5%)
constipation 11.7% (placebo 3.7%)
vomiting 11.7% (placebo 1.2%)
NCT02827708 · Phase 3
14 mg
nausea 22.7% (placebo 7.1%)
diarrhoea 14.4% (placebo 6%)
decreased appetite 12.7% (placebo 1.1%)
NCT03021187 · Phase 3
7 mg
nausea 16.6% (placebo 7.1%)
diarrhoea 12.2% (placebo 6%)
nasopharyngitis 11.6% (placebo 14.7%)
NCT03021187 · Phase 3
3 mg
nasopharyngitis 14.7% (placebo 14.7%)
nausea 11.4% (placebo 7.1%)
diarrhoea 8.7% (placebo 6%)
NCT03021187 · Phase 3
diabetic retinopathy 19.5% (placebo 19.3%)
covid-19 15.7% (placebo 16.1%)
nausea 7.1% (placebo 1.3%)
NCT03914326 · Phase 3
covid-19 8.8%
nausea 7.6%
NCT05035082 · Phase 4 · registry result, not featured evidence
14 mg once daily
nausea 18%
diarrhoea 12.4%
covid-19 11.8%
NCT04707469 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 27.3%
vomiting 18.2%
diarrhoea 14.2%
NCT04707469 · Phase 3 · registry result, not featured evidence
25 mg once daily
nausea 27.2%
vomiting 17%
diarrhoea 12.9%
NCT04707469 · Phase 3 · registry result, not featured evidence
14 mg
diarrhoea 13.3%
nausea 12.2%
decreased appetite 9.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
7 mg
nausea 10.9%
diarrhoea 8.9%
decreased appetite 8.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
3 mg
nausea 10%
diarrhoea 8.3%
upper respiratory tract infection 7.2%
NCT04017832 · Phase 3 · registry result, not featured evidence
14 mg
decreased appetite 10.9% (placebo 0%)
diarrhoea 9.3% (placebo 1.5%)
upper respiratory tract infection 7% (placebo 4.6%)
NCT04109547 · Phase 3 · registry result, not featured evidence
7 mg
diarrhoea 9.2% (placebo 1.5%)
upper respiratory tract infection 9.2% (placebo 4.6%)
lipase increased 8.5% (placebo 0%)
NCT04109547 · Phase 3 · registry result, not featured evidence
3 mg
upper respiratory tract infection 8.5% (placebo 4.6%)
lipase increased 5.4% (placebo 0%)
nausea 4.6% (placebo 1.5%)
NCT04109547 · Phase 3 · registry result, not featured evidence
nausea 20.9%
nasopharyngitis 10.3%
headache 9.9%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 22.9%
nasopharyngitis 13.4%
diarrhoea 11.5%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 17%
diarrhoea 10%
nasopharyngitis 7%
NCT02849080 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 18.8% (placebo 28.6%)
constipation 12.5% (placebo 6.1%)
decreased appetite 12.5% (placebo 0%)
NCT03018028 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 16.3% (placebo 28.6%)
constipation 12.2% (placebo 6.1%)
nausea 10.2% (placebo 2%)
NCT03018028 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 20.4% (placebo 28.6%)
constipation 10.2% (placebo 6.1%)
periarthritis 10.2% (placebo 4.1%)
NCT03018028 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 30%
constipation 15.4%
nausea 9.2%
NCT03015220 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 29.5%
constipation 12.1%
decreased appetite 9.1%
NCT03015220 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 26%
constipation 9.2%
influenza 6.9%
NCT03015220 · Phase 3 · registry result, not featured evidence
40 mg
nausea 33.8% (placebo 1.4%)
vomiting 19.7% (placebo 4.2%)
decreased appetite 14.1% (placebo 1.4%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 35.7% (placebo 1.4%)
vomiting 22.9% (placebo 4.2%)
diarrhoea 17.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 32.9% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 15.7% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
20 mg
nausea 35.7% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 17.1% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
10 mg
nausea 33.3% (placebo 1.4%)
diarrhoea 23.2% (placebo 9.9%)
vomiting 20.3% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
5 mg
nausea 14.3% (placebo 1.4%)
headache 12.9% (placebo 5.6%)
diarrhoea 10% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
2.5 mg
nausea 12.9% (placebo 1.4%)
nasopharyngitis 8.6% (placebo 12.7%)
diarrhoea 7.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 32 weeks versus 104 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
  8. hAssessment timepoints differ: 84 weeks versus 104 weeks.
  9. iPopulation comparability has not been reviewed for 32 of these studies.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Victoza)

MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
HbA1c Less Than 7% 63.7% (n=66) vs 36.5% (n=68) placebo @ 26wk1.8 mg
responder rate · % of participants
NCT01541215 · Phase 3
show 3 more results
44% (n=46) vs 20% (n=44) Metformin, Insulin Detemir, Insulin Aspart @ 26wk
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
76.5% (n=162) vs 52.6% (n=175) Sitagliptin @ 26wk
NCT02008682 · Phase 4 · registry result, not featured evidence
51.79% (n=195) vs 23.16% (n=95) placebo @ 26wk
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
BMI SDS -0.254 vs -0.208 placebo score @ 26wk1.8 mg
absolute change · score
NCT01541215 · Phase 3
show 1 more result
-0.361 vs -0.166 placebo score @ 52wk1.8 mg
NCT01541215 · Phase 3
HbA1c Less Than 7 Without Hypoglycemia 52.5% (n=59) vs 36.2% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 31 Participants as posted
show 3 more results
39.3% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 22 Participants as posted
44.7% (n=76) vs 33% (n=88) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
48.2% (n=83) vs 33% (n=94) Glargine @ 12wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
HbA1c Less Than 7 5 72.9% (n=59) vs 50% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 43 Participants as posted
show 1 more result
64.3% (n=56) vs 44.2% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 36 Participants as posted
HbA1c 7.13% (n=136) vs 7.68% (n=137) Glargine @ 26wk
absolute value · percentage points
HbA1C at 6 months post-intervention
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Weight Gain 33% (n=996) vs 23.5% (n=995) Oral Antidiabetic Drug @ 104wk1.8 mg
event count · % of participants
NCT02730377 · Phase 4 · registry result, not featured evidence · converted to % from 329 Participants as posted
show 8 more results
41% (n=78) vs 23.3% (n=90) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted
40.7% (n=361) vs 19% (n=179) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 147 Participants as posted
41.1% (n=180) vs 19% (n=179) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 74 Participants as posted
32.5% (n=302) vs 4.6% (n=151) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 98 Participants as posted
16% (n=275) vs 8.1% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 44 Participants as posted
52% (n=273) vs 8.1% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 142 Participants as posted
47.6% (n=105) vs 8.6% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 50 Participants as posted
43.3% (n=210) vs 18.1% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 91 Participants as posted
Weight -4.77 vs 0.6 Glargine Kgs @ 26wk
absolute change · Kgs
Weight change from baseline (discharge) to 6 months after discharge
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
BMI 32.7 vs 33.3 Glargine kg @ 26wk
absolute value · kg
BMI at 26 weeks follow up
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
Total Daily Insulin Dose 0 vs 20.9 Glargine per day @ 26wk
absolute value · per day
NCT01919489 · Phase 4 · registry result, not featured evidence · combination

+ 107 further endpoints in the CSV export.

Semaglutide (Rybelsus)

HbA1c -1.5% (n=175) vs -0.3% (n=178) placebo @ 26wk14 mg
absolute change · percentage points
In-trial
NCT02906930 · Phase 3
show 11 more results
-1.3% (n=411) vs -0.9% (n=410) Empagliflozin 25 mg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-1.3% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-1.2% (n=285) vs -0.1% (n=142) placebo @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-1.1% (n=163) vs -0.2% (n=161) placebo @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-1.3% (n=181) vs -0.1% (n=184) placebo @ 26wk14 mg
In-trial
NCT03021187 · Phase 3
-1.3% (n=175) vs -0.3% (n=178) placebo @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-1.1% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1% (n=182) vs -0.1% (n=184) placebo @ 26wk7 mg
In-trial
NCT03021187 · Phase 3
-0.9% (n=175) vs -0.3% (n=178) placebo @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-0.6% (n=466) vs -0.8% (n=467) Sitagliptin @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-0.5% (n=184) vs -0.1% (n=184) placebo @ 26wk3 mg
In-trial
NCT03021187 · Phase 3
Weight -4 vs -1.4 placebo kg @ 26wk14 mg
absolute change · kg
In-trial
NCT02906930 · Phase 3
show 9 more results
-3.9 vs -3.8 Empagliflozin 25 mg kg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-3.1 vs -0.6 Sitagliptin kg @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-4.4 vs -0.6 placebo kg @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-3.5 vs -0.9 placebo kg @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-2.6 vs -1.4 placebo kg @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-2.2 vs -0.6 Sitagliptin kg @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1.5 vs -1.4 placebo kg @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-1.2 vs -0.6 Sitagliptin kg @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-2.7 vs -0.7 Sitagliptin kg @ 52wk
In-trial
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c 6.5 or Less 63.8% (n=160) vs 17.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 102 Participants as posted
show 2 more results
47.5% (n=160) vs 17.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 76 Participants as posted
35.9% (n=167) vs 17.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 60 Participants as posted
Weight Loss 5% 41.3% (n=160) vs 14.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 66 Participants as posted
show 11 more results
35.7% (n=154) vs 9.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 55 Participants as posted
44.7% (n=333) vs 8% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
37.1% (n=116) vs 10.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
26.9% (n=160) vs 14.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 43 Participants as posted
31.3% (n=342) vs 8% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
24.4% (n=119) vs 10.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
19.6% (n=168) vs 14.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 33 Participants as posted
16% (n=343) vs 8% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
14.8% (n=115) vs 10.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
36.9% (n=298) vs 31.9% (n=260) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted
27% (n=233) vs 12.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 63 Participants as posted
Weight Loss 10% 14.4% (n=160) vs 1.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 23 Participants as posted
show 10 more results
8.4% (n=154) vs 0% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 13 Participants as posted
12.6% (n=333) vs 0.6% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 42 Participants as posted
10.3% (n=116) vs 0% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 12 Participants as posted
8.1% (n=160) vs 1.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
7% (n=342) vs 0.6% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
5.9% (n=119) vs 0% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
2.4% (n=168) vs 1.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
1.5% (n=343) vs 0.6% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.3% (n=115) vs 0% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
6.4% (n=233) vs 2.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
HbA1c Reduction 1% and Weight Loss 3% 50.6% (n=160) vs 10.7% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 81 Participants as posted
show 10 more results
39% (n=154) vs 7.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 60 Participants as posted
47.9% (n=332) vs 9.4% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 159 Participants as posted
45.7% (n=116) vs 9.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
36.9% (n=160) vs 10.7% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 59 Participants as posted
37.8% (n=339) vs 9.4% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 128 Participants as posted
36.8% (n=117) vs 9.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
18% (n=167) vs 10.7% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 30 Participants as posted
18.6% (n=344) vs 9.4% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
22.8% (n=114) vs 9.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
34.8% (n=230) vs 10.5% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
Time to Additional Anti-diabetic Medication 4% (n=175) vs 19.7% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 7 Participants as posted
show 36 more results
4.1% (n=411) vs 3.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 17 Participants as posted
12.7% (n=411) vs 13.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 52 Participants as posted
3.2% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 15 Participants as posted
11% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 51 Participants as posted
16.1% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 75 Participants as posted
7% (n=285) vs 8.5% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
13.7% (n=285) vs 32.4% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 39 Participants as posted
7.4% (n=163) vs 13% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 12 Participants as posted
4.4% (n=181) vs 6% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.3% (n=181) vs 40.8% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 44 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
4.6% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
6.2% (n=130) vs 12.3% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.6% (n=175) vs 19.7% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 8 Participants as posted
4.3% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 20 Participants as posted
18.5% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 86 Participants as posted
25.6% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 119 Participants as posted
4.4% (n=182) vs 6% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.7% (n=182) vs 40.8% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 45 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
12.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.3% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
9.8% (n=132) vs 12.3% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
9.1% (n=175) vs 19.7% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 16 Participants as posted
7.1% (n=466) vs 4.3% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 33 Participants as posted
29.4% (n=466) vs 23.8% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 137 Participants as posted
38.4% (n=466) vs 31.7% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 179 Participants as posted
4.9% (n=184) vs 6% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 9 Participants as posted
33.2% (n=184) vs 40.8% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 61 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
16.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
0.8% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
18.3% (n=131) vs 12.3% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
8.7% (n=253) vs 18.7% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
15% (n=100) vs 26.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
Time to Rescue Medication 1.1% (n=175) vs 15.2% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 2 Participants as posted
show 39 more results
1.9% (n=411) vs 1.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 8 Participants as posted
7.5% (n=411) vs 10.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 31 Participants as posted
1.1% (n=465) vs 2.8% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 5 Participants as posted
6.7% (n=465) vs 20.1% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 31 Participants as posted
10.1% (n=465) vs 27.6% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 47 Participants as posted
3.5% (n=285) vs 7.7% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 10 Participants as posted
7% (n=285) vs 30.3% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
4.3% (n=163) vs 9.9% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 7 Participants as posted
2.2% (n=181) vs 4.9% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 4 Participants as posted
17.1% (n=181) vs 36.4% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 31 Participants as posted
1.7% (n=361) vs 1.9% (n=359) Sitagliptin*14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
0.8% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
1.5% (n=130) vs 9.2% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
2.3% (n=175) vs 15.2% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
2.4% (n=465) vs 2.8% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 11 Participants as posted
15.7% (n=465) vs 20.1% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 73 Participants as posted
22.2% (n=465) vs 27.6% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 103 Participants as posted
1.1% (n=182) vs 4.9% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 2 Participants as posted
18.1% (n=182) vs 36.4% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 33 Participants as posted
1.7% (n=360) vs 1.9% (n=359) Sitagliptin*7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
4.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
10.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
0% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
6.1% (n=132) vs 9.2% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
7.4% (n=175) vs 15.2% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
5.4% (n=466) vs 2.8% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 25 Participants as posted
26% (n=466) vs 20.1% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 121 Participants as posted
34.3% (n=466) vs 27.6% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 160 Participants as posted
2.7% (n=184) vs 4.9% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 5 Participants as posted
29.3% (n=184) vs 36.4% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 54 Participants as posted
1.4% (n=361) vs 1.9% (n=359) Sitagliptin*3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
14.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
0% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
16.8% (n=131) vs 9.2% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
3.2% (n=253) vs 15.9% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
9% (n=100) vs 23.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 9 Participants as posted
Free Fatty Acids 0.95 vs 1.05 Empagliflozin 25 mg ratio @ 26wk14 mg
absolute change · ratio
NCT02863328 · Phase 3
show 1 more result
0.88 vs 0.97 Empagliflozin 25 mg ratio @ 52wk14 mg
NCT02863328 · Phase 3
HbA1c Less Than 7% 63.7% (n=411) vs 38.5% (n=410) Empagliflozin 25 mg @ 26wk14 mg
event count · % of participants
Week 26 · Yes
NCT02863328 · Phase 3 · converted to % from 262 Participants as posted
show 10 more results
66% (n=285) vs 13.4% (n=142) placebo @ 26wk*14 mg
Week 26 · Yes
NCT02863419 · Phase 3 · converted to % from 188 Participants as posted
55.8% (n=181) vs 6.5% (n=184) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 101 Participants as posted
72.9% (n=48) vs 12.2% (n=49) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 35 Participants as posted
80.8% (n=130) vs 69.2% (n=65) Dulaglutide @ 26wk*14 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 105 Participants as posted
40.7% (n=182) vs 6.5% (n=184) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 74 Participants as posted
67.3% (n=49) vs 12.2% (n=49) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
72.7% (n=132) vs 69.2% (n=65) Dulaglutide @ 26wk*7 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
27.2% (n=184) vs 6.5% (n=184) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 50 Participants as posted
49% (n=49) vs 12.2% (n=49) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
45% (n=131) vs 69.2% (n=65) Dulaglutide @ 26wk*3 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 59 Participants as posted
HbA1c Less Than 7% 61.8% (n=411) vs 40.2% (n=410) Empagliflozin 25 mg @ 52wk14 mg
event count · % of participants
Week 52 · Yes
NCT02863328 · Phase 3 · converted to % from 254 Participants as posted
show 10 more results
58.6% (n=285) vs 14.1% (n=142) placebo @ 52wk*14 mg
Week 52 · Yes
NCT02863419 · Phase 3 · converted to % from 167 Participants as posted
50.3% (n=181) vs 8.7% (n=184) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 91 Participants as posted
68.8% (n=48) vs 8.2% (n=49) placebo @ 52wk*14 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
69.2% (n=130) vs 49.2% (n=65) Dulaglutide @ 52wk*14 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 90 Participants as posted
36.8% (n=182) vs 8.7% (n=184) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 67 Participants as posted
59.2% (n=49) vs 8.2% (n=49) placebo @ 52wk*7 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
58.3% (n=132) vs 49.2% (n=65) Dulaglutide @ 52wk*7 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 77 Participants as posted
27.2% (n=184) vs 8.7% (n=184) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03021187 · Phase 3 · converted to % from 50 Participants as posted
38.8% (n=49) vs 8.2% (n=49) placebo @ 52wk*3 mg
Week 52 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
32.8% (n=131) vs 49.2% (n=65) Dulaglutide @ 52wk*3 mg
Week 52 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
HbA1c Less Than or Equal to 6.5 45.3% (n=411) vs 16.6% (n=410) Empagliflozin 25 mg @ 26wk14 mg
event count · % of participants
Week 26 · Yes
NCT02863328 · Phase 3 · converted to % from 186 Participants as posted
show 12 more results
34.6% (n=465) vs 13.1% (n=467) Sitagliptin @ 26wk*14 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 161 Participants as posted
40.9% (n=181) vs 3.3% (n=184) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 74 Participants as posted
58.3% (n=48) vs 4.1% (n=49) placebo @ 26wk*14 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 28 Participants as posted
67.7% (n=130) vs 47.7% (n=65) Dulaglutide @ 26wk*14 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 88 Participants as posted
24.9% (n=465) vs 13.1% (n=467) Sitagliptin @ 26wk*7 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 116 Participants as posted
24.7% (n=182) vs 3.3% (n=184) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 45 Participants as posted
49% (n=49) vs 4.1% (n=49) placebo @ 26wk*7 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
50.8% (n=132) vs 47.7% (n=65) Dulaglutide @ 26wk*7 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
11.8% (n=466) vs 13.1% (n=467) Sitagliptin @ 26wk*3 mg
Week 26 · Yes
NCT02607865 · Phase 3 · converted to % from 55 Participants as posted
13% (n=184) vs 3.3% (n=184) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03021187 · Phase 3 · converted to % from 24 Participants as posted
26.5% (n=49) vs 4.1% (n=49) placebo @ 26wk*3 mg
Week 26 · Yes
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
30.5% (n=131) vs 47.7% (n=65) Dulaglutide @ 26wk*3 mg
Week 26 · Yes
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 40 Participants as posted

+ 106 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · Semaglutide (Rybelsus)'s landscape